多配体蛋白聚糖-1限制对乙酰氨基酚诱导的小鼠肝损伤进展并促进肝脏修复
本文在小鼠对乙酰氨基酚(APAP)肝损伤模型中研究肝细胞主要细胞表面硫酸乙酰肝素蛋白聚糖多配体蛋白聚糖-1的作用。多配体蛋白聚糖-1缺失小鼠在APAP过量后肝损伤无对抗地持续进展,而给予纯化多配体蛋白聚糖-1、硫酸乙酰肝素或含2-O-硫酸基团的工程化肝素类化合物可通过增强Akt信号、抑制GSK-3β介导的肝细胞凋亡挽救Sdc1-/-小鼠。
要点
- 多配体蛋白聚糖-1缺失导致小鼠APAP过量后肝损伤无对抗地进展。
- 纯化多配体蛋白聚糖-1、硫酸乙酰肝素或含2-O-硫酸基团的工程化肝素类化合物可挽救Sdc1-/-小鼠。
- 硫酸乙酰肝素的治疗疗效较N-乙酰半胱氨酸显著延长。
核心结论
- 多配体蛋白聚糖-1硫酸乙酰肝素中的2-O-硫酸化结构域通过增强肝细胞存活阻止对乙酰氨基酚肝损伤疾病进展并促进肝脏修复。
- 作者提出多配体蛋白聚糖-1是控制对乙酰氨基酚肝病中肝细胞促存活信号与凋亡平衡的关键内源性因子。
研究设计与样本
- 研究为小鼠对乙酰氨基酚诱导肝损伤模型的实验研究,比较野生型与多配体蛋白聚糖-1缺失(Sdc1-/-)小鼠。
- 使用纯化多配体蛋白聚糖-1、硫酸乙酰肝素及含2-O-硫酸基团的工程化肝素类化合物进行干预,并与N-乙酰半胱氨酸比较疗效。
主要发现
- 多配体蛋白聚糖-1缺失小鼠在APAP过量后肝损伤无对抗地进展,但APAP直接肝毒性和过量后早期肝损伤不受多配体蛋白聚糖-1影响。
- Sdc1-/-小鼠过度肝损伤表型归因于肝细胞蛋白激酶B(Akt)活化缺陷,导致糖原合成酶激酶-3β(GSK-3β)介导的肝细胞凋亡延迟增加。
- 抑制Akt加重而抑制GSK-3β和半胱天冬酶保护小鼠免于APAP诱导肝损伤。
- 给予纯化多配体蛋白聚糖-1、硫酸乙酰肝素或含2-O-硫酸基团的工程化肝素类化合物可通过增强Akt信号并抑制GSK-3β介导的肝细胞凋亡挽救Sdc1-/-小鼠。
- 硫酸乙酰肝素与N-乙酰半胱氨酸相比显示出显著延长的治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Accidental or intentional misuse of acetaminophen (APAP) is the leading cause of acute liver failure in the Western world. Although mechanisms that trigger APAP-induced liver injury (AILI) are well known, those that halt the progression of APAP liver disease and facilitate liver recovery are less understood. Heparan sulfate proteoglycans (HSPGs) bind to and regulate various tissue injury factors through their heparan sulfate (HS) chains, but the importance of HSPGs in liver injury in vivo remains unknown. Here, we examined the role of syndecan-1, the major cell-surface HSPG of hepatocytes, in AILI. Ablation of syndecan-1 in mice led to unopposed progression of liver injury upon APAP overdose. However, direct APAP hepatoxicity and liver injury at early times post-APAP overdose were unaffected by syndecan-1, suggesting that syndecan-1 influences later mechanisms that lead to liver repair. The exuberant liver injury phenotypes in syndecan-1 null (Sdc1-/- ) mice were traced to a deficiency in protein kinase B (Akt) activation in hepatocytes, which led to a delayed increase in glycogen synthase kinase-3β (GSK-3β)-mediated hepatocyte apoptosis. Inhibition of Akt worsened, whereas inhibition of GSK-3β and caspases protected mice from AILI. Moreover, administration of purified syndecan-1, HS, or engineered heparan compounds containing 2-O-sulfate groups rescued Sdc1-/- mice from AILI by potentiating Akt signaling and inhibiting GSK-3β-mediated apoptosis in hepatocytes. In addition, HS showed a significantly prolonged therapeutic efficacy as compared to N-acetylcysteine. CONCLUSION: These results demonstrate that 2-O-sulfated domains in syndecan-1 HS halt disease progression and promote liver repair by enhancing hepatocyte survival in AILI. We propose that syndecan-1 is a critical endogenous factor that controls the balance between prosurvival signaling and apoptosis in hepatocytes in APAP liver disease. (Hepatology 2017;66:1601-1615).
引用
- Nam EJ, Hayashida K, Aquino RS, et al. Syndecan-1 limits the progression of liver injury and promotes liver repair in acetaminophen-induced liver injury in mice. Hepatology. 2017. PMID: 28543100. doi:10.1002/hep.29265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。